| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $415.47 | $3,323,728.21 | -48.6% | +14.0% | - | |
| Oct 27, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael | President And COO | Sell | 22,500 | $417.50 | $9,393,671.25 | -99.4% | +12.4% | - | |
| Oct 27, 2025 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 692 | $22.93 | $15,867.56 | -0.4% | +85.5% | - | |
| Oct 27, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,637 | $50.10 | $132,113.70 | -1.6% | -37.2% | - | |
| Oct 27, 2025 | LQDA Liquidia Corp | Boyle Dana | Chief Accounting Officer | Sell | 1,073 | $22.93 | $24,603.89 | -0.6% | +85.5% | - | |
| Oct 24, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $423.12 | $3,384,988.91 | -64.8% | +12.8% | - | |
| Oct 24, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 18,899 | $40.53 | $765,941.11 | -9.7% | -1.7% | - | |
| Oct 22, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $424.96 | $3,399,649.78 | -43.6% | +11.0% | - | |
| Oct 22, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 257,969 | $38.86 | $10,023,531.59 | -35.5% | +5.5% | - | |
| Oct 22, 2025 | PLNH Planet 13 Holdings Inc. | Wren Chris | VP Of Operations | Sell | 30,000 | $0.22 | $6,600.00 | -0.3% | - | - | |
| Oct 20, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 50,490 | $38.87 | $1,962,781.45 | -42.9% | +5.2% | - | |
| Oct 20, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael | President And COO | Sell | 22,500 | $427.41 | $9,616,702.50 | -100% | +8.2% | - | |
| Oct 20, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $427.63 | $3,421,036.55 | -50.0% | +8.2% | - | |
| Oct 20, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 16,775 | $40.37 | $677,198.35 | -20.8% | +1.1% | - | |
| Oct 17, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,592 | $57.13 | $662,221.98 | -14.2% | -37.3% | - | |
| Oct 17, 2025 | JNJ Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4,185,793.09 | -67.1% | +13.6% | - | |
| Oct 17, 2025 | ESPR Esperion Therapeutics, Inc. | Looker Benjamin56 | General Counsel | Sell | 1,248 | $2.62 | $3,275.38 | -0.3% | +13.8% | - | |
| Oct 16, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 175,661 | $62.79 | $11,029,998.77 | -16.1% | -47.0% | - | |
| Oct 16, 2025 | UTHR United Therapeutics Corp | Mahon Paul A | EVP &General Counsel | Sell | 11,000 | $431.50 | $4,746,494.14 | -3.3% | +9.9% | - | |
| Oct 16, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $433.30 | $3,466,416.77 | -46.7% | +9.9% | - | |
| Oct 15, 2025 | AQST Aquestive Therapeutics, Inc. | Jung Cassie | Chief Operating Officer | Sell | 67,575 | $7.01 | $473,700.75 | -21.9% | -53.4% | - | |
| Oct 15, 2025 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 9,000 | $31.53 | $283,776.30 | -10.9% | -9.6% | - | |
| Oct 15, 2025 | AQST Aquestive Therapeutics, Inc. | Boyd Peter E.81 | See Remarks | Sell | 10,000 | $7.00 | $70,000.00 | -3.6% | -53.4% | - | |
| Oct 15, 2025 | AQST Aquestive Therapeutics, Inc. | Kraus Carl N | Chief Medical Officer | Sell | 20,272 | $7.00 | $141,904.00 | -6.7% | -53.4% | - | |
| Oct 14, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 12,368 | $37.67 | $465,843.22 | -17.6% | +8.5% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.